Mi az ára Infinity Pharmaceuticals, Inc. (INFI)

Infinity Pharmaceuticals, Inc. (INFI) ára $0.0039

Mi a Infinity Pharmaceuticals, Inc. (INFI piaci tőkésítése)

Infinity Pharmaceuticals, Inc. piaci tőkésítése (INFI) $235.97K

Infinity Pharmaceuticals, Inc. (INFI) Ár és Piaci Kapitalizáció

Infinity Pharmaceuticals, Inc., established in 1995 and based in Cambridge, Massachusetts, operates as a biopharmaceutical firm dedicated to creating innovative therapies for individuals battling cancer. A central component of its pipeline is IPI-549, an experimental immuno-oncology drug taken orally. This candidate, currently in clinical development, functions by blocking the phosphoinositide-3-kinase-gamma enzyme. IPI-549 is undergoing Phase 2 trials for metastatic triple negative breast cancer and urothelial cancer, and Phase 1/1b trials for various solid tumors. The company maintains several strategic partnerships: with Intellikine, Inc. for the discovery, development, and commercialization of PI3K delta and/or gamma isoform-targeting pharmaceuticals; with Verastem, Inc. for the research, development, commercialization, and production of duvelisib and related compounds; and with PellePharm, Inc. to advance and commercialize its hedgehog inhibitor program, IPI-926, which is also a clinical-stage investigational drug. Furthermore, Infinity Pharmaceuticals holds collaborative agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company.

A INFI ára	B aktíva	A B piaci tőkésítése	Eredmények
$90,396.06 $235.97K	NVDA	$5.470T	+2,317,847,615.15%
$73,828.11 $235.97K	AAPL	$4.467T	+1,893,028,379.22%
$68,990.85 $235.97K	GOOG	$4.174T	+1,768,996,165.18%
$61,151.86 $235.97K	MSFT	$3.700T	+1,567,996,335.13%
$47,174.25 $235.97K	AMZN	$2.854T	+1,209,596,025.46%

A INFI ára

B aktíva

A B piaci tőkésítése

Eredmények

$90,396.06 $235.97K